stonks4u
Log inSign up free
AVXL logo

AVXL Anavex Life Sciences Corp.

NASDAQ Global Select · Biotechnology · Healthcare

$3.19
-0.03 (-0.93%)

Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer's disease and pediatric Rett syndrome. This same drug is also in Phase II tri…

Market Cap: $295.62Mwww.anavex.com

Price

No data yet.

Signal Score (90d)

100
100
Aug 17Aug 17

Quote

Day Range
$3.15 – $3.26
52-Week Range
$2.25 – $10.40
Volume
$82.9K
Market Cap
$295.62M
50-Day Avg
$2.70
200-Day Avg
$3.77
Prev Close
$3.22
Open
$3.26

Valuation & Ratios

P/E Ratio
-16.48
EPS
$-0.54
P/B Ratio
8.00
P/S Ratio
0.00
Debt/Equity
0.00
Current Ratio
11.60
Dividend Yield
+0.0%
Gross Margin
+0.0%

Returns & Efficiency

Return on Equity
-48.9%
Return on Assets
-44.7%
FCF Yield
-5.1%
EV/EBITDA
-14.16

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$0.00$-46.38M$-0.54
2024$0.00$-43.00M$-0.52
2023$0.00$-47.51M$-0.60
2022$0.00$-47.98M$-0.62
2021$0.00$-37.91M$-0.54

Social Signal Score

50
5d
51
1 mentions
—
30d
50
1 mentions
—
60d
50
1 mentions
—
90d
50
1 mentions
—
news: 1

Earnings

Mon, Nov 30(in 3 months)

Consensus estimate $-0.11 per share

6of 7 quarters beat consensus

Typical surprise +17.6% (median, so one quarter with a near-zero estimate can't distort it)

  • Mon, Aug 17$-0.06 vs $-0.08beat
  • Mon, Feb 9$-0.06 vs $-0.10beat
  • Tue, Nov 25$-0.11 vs $-0.13beat
  • Tue, Aug 12$-0.16 vs $-0.13miss
  • Tue, May 13$-0.13 vs $-0.16beat
  • Wed, Feb 12$-0.14 vs $-0.17beat

Estimates and results for AVXL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Insider trading

Open-market buys and sells by AVXL officers and directors.

Bought
$44k

3 trades

Sold
$10.4m

6 trades

  • Donhauser Peter D.o.bought
    director·2,835 @ $3.64·$10k·Jun 14, 2024·filing
  • Thomas Steffenbought
    director·5,000 @ $4.52·$23k·May 15, 2024·filing
  • Missling Christopher Usold
    director, officer: President and CEO·73,380 @ $5.11·$375k·Mar 28, 2024·filing
  • Missling Christopher Usold
    director, officer: President and CEO·268,000 @ $7.98·$2.1m·Jun 28, 2023·filing
  • Skarpelos Athanasiossold
    director:·50,000 @ $9.06·$453k·May 25, 2022·filing
  • Missling Christopher Usold
    director, officer: President and CEO·51,620 @ $26.00·$1.3m·Jun 29, 2021·filing
  • Boenisch Sandrasold
    PFO and Treasurer·166,696 @ $26.53·$4.4m·Jun 29, 2021·filing
  • Favus Elliotsold
    director·145,000 @ $11.70·$1.7m·May 21, 2021·filing

91 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.

Valuation

AVXLhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newsglobenewswire.com·6h ago·Neutral

    Anavex Life Sciences Mails Letter to Stockholders Reinforcing Relevant Experience of All Six Director Nominees Launches  VoteAnavex.com to Provide Additional Information on Anavex's Director Nominees and How to Vote at the Annual Meeting of Stockholders

    View source ↗